biostudies-literatureSirasanagandla SRSultan Qaboos University36https://www.ebi.ac.uk/biostudies/studies/S-EPMC8727657biostudies-literatureUnknown12(1)Current evidence suggests that intrauterine bisphenol A (BPA) exposure increases the risk of developing cardiovascular diseases in later stages of life. The beneficial effect of resveratrol (Rsv) on developmental programming of atherosclerosis lesions formation in offspring is seldom reported. Hence, we sought to study the effect of maternal Rsv in ameliorating perinatal BPA exposure-induced atherosclerosis lesions formation in adult offspring using the apolipoprotein E-deficient (ApoE^-/-) mice model. The pregnant ApoE^-/- mice were allocated into three groups: control, BPA, BPA + <i>resveratrol</i> (BPA + Rsv). The BPA group mice received BPA in their drinking water (1 μg/ml). BPA + Rsv group mice received BPA in their drinking water (1 μg/ml) and were treated orally 3 BiotechMaternal resveratrol supplementation ameliorates bisphenol A-induced atherosclerotic lesions formation in adult offspring ApoE^-/- mice.PMC8727657IG/MED/ANAT/18/01Sirasanagandla SRAl-Abri NAl-Huseini IAl-Ghafri FAl Mushaiqri MfalseMaternal resveratrol supplementation ameliorates bisphenol A-induced atherosclerotic lesions formation in adult offspring ApoE^-/- mice.Current evidence suggests that intrauterine bisphenol A (BPA) exposure increases the risk of developing cardiovascular diseases in later stages of life. The beneficial effect of resveratrol (Rsv) on developmental programming of atherosclerosis lesions formation in offspring is seldom reported. Hence, we sought to study the effect of maternal Rsv in ameliorating perinatal BPA exposure-induced atherosclerosis lesions formation in adult offspring using the apolipoprotein E-deficient (ApoE^-/-) mice model. The pregnant ApoE^-/- mice were allocated into three groups: control, BPA, BPA + <i>resveratrol</i> (BPA + Rsv). The BPA group mice received BPA in their drinking water (1 μg/ml). BPA + Rsv group mice received BPA in their drinking water (1 μg/ml) and were treated orally 2022-01-01T00:00:00Z2022 Jan2025-04-21T15:16:39.556Z2025-02-19T03:30:55.023ZS-EPMC87276573507062610.1007/s13205-021-03078-y